EDX医疗组和Caris生命科学公司在联合王国和北欧国家签订了一项为期三年的AI驱动癌症诊断分发协议。 EDX Medical Group and Caris Life Sciences enter a three-year distribution deal for AI-driven cancer diagnosis in the UK and Nordic countries.
EDX医疗小组与Caris生命科学签订了一项为期三年的分发协议,在联合王国和北欧国家分发先进的分子特征分析服务。 EDX Medical Group has entered a three-year distribution agreement with Caris Life Sciences to distribute advanced molecular profiling services in the UK and Nordic countries. 这一合作旨在通过AI驱动的诊断,评估DNA、RNA和蛋白质,加强个人化癌症治疗。 This collaboration aims to enhance personalized cancer treatment through AI-driven diagnostics that assess DNA, RNA, and proteins. 该协议使EDX能够向临床医生提供这些服务,改善治疗决策和癌症护理的病人结果。 The agreement enables EDX to provide these services to clinicians, improving treatment decision-making and patient outcomes in cancer care.